The central challenge for COMPACT is to develop suitable formulations that will facilitate the transport of biopharmaceuticals (BP), with an emphasis on peptides, proteins and nucleic acids, over a number of biological barriers (skin, blood-brain, intestines and lungs) with subsequent delivery of the BP cargo to the intended target tissues or cells. In order to meet this key objective, several successive steps will be followed that should ultimately lead to selection of suitable formulations for efficient transport of BP over various barriers.
- Formulation of model-and disease specific BPs using chemical & biological engineering, bioconjugation and encapsulation in drug delivery systems (DDS) (WP1&2)
- High-throughput in vitro testing for cellular uptake, toxicity and immunogenicity (WP3)
- Low throughput, high content screening of cellular trafficking (WP3)
- In vitro testing of barrier transport of drug delivery systems (WP4-7)
- In vivo testing of barrier transport of drug delivery systems(WP4-7)
- In vivo efficacy testing of drug delivery systems in disease specific animal models (WP4-7)An overview of the structure of the proposed work plan with the different work packages and their connections is shown in figure 1.
Figure 1: Overview of the COMPACT work plan with the interconnected work packages